Solute carrier family 9, subfamily A, member 3 (SLC9A3)/sodium-hydrogen exchanger member 3 (NHE3) dysregulation and dilated intercellular spaces in patients with eosinophilic esophagitis 
STAT6 ↑[H + ]/ ↓ pH i
Background: Eosinophilic esophagitis (EoE) is characterized by histopathologic modifications of esophageal tissue, including eosinophil-rich inflammation, basal zone hyperplasia, and dilated intercellular spaces (DIS). The underlying molecular processes that drive the histopathologic features of EoE remain largely unexplored. Objective: We sought to investigate the involvement of solute carrier family 9, subfamily A, member 3 (SLC9A3) in esophageal epithelial intracellular pH (pH i ) and DIS formation and the histopathologic features of EoE. Methods: We examined expression of esophageal epithelial gene networks associated with regulation of pH i in the EoE transcriptome of primary esophageal epithelial cells and an in vitro esophageal epithelial 3-dimensional model system (EPC2-ALI). Molecular and cellular analyses and ion transport assays were used to evaluate the expression and function of SLC9A3. Results: We identified altered expression of gene networks associated with regulation of pH i and acid-protective mechanisms in esophageal biopsy specimens from pediatric patients with EoE (healthy subjects, n 5 6; patients with EoE, n 5 10). The most dysregulated gene central to regulating pH i was SLC9A3. SLC9A3 expression was increased within the basal layer of esophageal biopsy specimens from patients with EoE, and expression positively correlated with disease severity (eosinophils/high-power field) and DIS (healthy subjects, n 5 10; patients with EoE, n 5 10). Analyses of esophageal epithelial cells revealed IL-13-induced, signal transducer and activator of transcription 6-dependent SLC9A3 expression and Na 1 -dependent proton secretion and that SLC9A3 activity correlated positively with DIS formation. Finally, we showed that IL-13-mediated, Na 1 -dependent proton secretion was the primary intracellular acid-protective mechanism within the esophageal epithelium and that blockade of SLC9A3 transport abrogated IL-13-induced DIS formation. Key words: Solute carrier family 9, subfamily A, member 3/ sodium-hydrogen exchanger member 3, ion transport, eosinophilic esophagitis, dilated intercellular spaces, Eosinophilic esophagitis (EoE) is a food allergen-induced inflammatory disease that is increasing in incidence (5-10 cases per 100,000) and prevalence (0.5-1 case per 1000). [1] [2] [3] [4] Common symptoms of EoE include vomiting, dysphagia, chest pain, food impaction, and upper abdominal pain 5 and decreased health-related quality of life. 6 Corroborative clinical and experimental studies indicate that an underlying allergic sensitization to dietary food antigens and development of a CD4
1 T H 2 and type 2 innate lymphoid cell inflammatory response in the esophageal mucosa drive eosinophilic inflammation and esophageal remodeling in patients with EoE, which includes basal zone hyperplasia (BZH) and dilated intercellular spaces (DIS). [7] [8] [9] [10] Dietary modification (ie, complete or targeted food antigen avoidance) and swallowed glucocorticoids alleviate much of the disease pathology, 11, 12 suggesting a food-induced CD4 1 type 2 allergic inflammatory response. [13] [14] [15] [16] [17] [18] Consistent with this, animal-based studies have revealed important roles for CD4
1 T H 2 cells, proallergic cytokines (IL-5 and IL-13), and eosinophils in the histopathologic manifestations of disease. [19] [20] [21] One cytokine that seems to be central in orchestrating the EoE phenotype is IL-13.
22-24 IL-13 is highly upregulated in esophageal tissue of patients with EoE and is sufficient to alter gene expression in esophageal epithelial cells in vitro and in vivo, and the IL-13-induced transcriptome significantly overlaps with transcriptional changes observed in esophageal biopsy specimens of patients with EoE. [22] [23] [24] Importantly, treating patients with EoE with a humanized antibody against IL-13 led to a significant decrease in esophageal eosinophil counts and had a normalizing effect on the dysregulated transcriptome observed in patients with EoE. 25 IL-13 has been shown to dysregulate the expression of several key epithelial barrier regulatory genes, including desmosomal cadherin, desmoglein-1, leucine-rich repeat-containing protein 31 (LRRC31), kallikrein serine proteases, and calpain 14 (CAPN14), which have been linked to EoE. [26] [27] [28] Although there have been significant advances in our understanding of a link between allergic inflammation and EoE, there is a paucity of data revealing the underlying pathways that regulate the epithelial BZH and DIS in patients with EoE. The DIS, also described as spongiosis, is a morphologic feature that has been identified in multiple forms of esophagitis, including lymphocytic esophagitis, 29 gastroesophageal reflux disease (GERD), 30 and EoE. 8, 31 Histologic comparison between GERD and EoE suggests that DIS are significantly more intense in patients with EoE than in those with GERD. 32 Steroid therapy or an elimination diet significantly decreases DIS in patients with EoE, and this decrease is associated with improvement of patients' symptoms, 31 indicating an association between DIS and the cause of EoE. The underlying molecular pathways that drive DIS formation are currently unknown.
Recently, we performed RNA sequencing (RNAseq) on esophageal mucosal biopsy specimens from healthy control subjects and patients with active proton pump inhibitorconfirmed EoE. We identified a total of 1607 significantly dysregulated transcripts (1096 upregulated and 511 downregulated), with 66% of the gene signature being similar to the EoE transcript signature identified by means of microarray-based expression profiling. 24 We have performed Gene Ontology (GO) enrichment network analysis of the 1607 significantly dysregulated transcripts and identified dysregulation of transmembrane transporter activity genes associated with regulation of [pH] i and acid-protective mechanisms. The most dysregulated transmembrane transporter activity gene in the EoE transcriptome was the solute carrier family 9, subfamily A, member 3 (SLC9A3), which encodes sodium-hydrogen exchanger member 3 (NHE3; 33-fold increase). 33 We demonstrate a significant increase in SLC9A3 in the esophageal epithelium in 2 independent, confirmatory patient cohorts with proton pump inhibitorconfirmed EoE. We show that the expression level of NHE3 positively correlated with the level of inflammation and the area of the DIS. IL-13 treatment of esophageal epithelial primary cells derived from patients with EoE and in a differentiated squamous esophageal epithelium model (EPC2-ALI) increased NHE3 expression and ion transport activity. Pharmacologic inhibition of NHE3 function substantially decreased the area of IL-13-induced DIS. These collective data suggest that increased expression and activity of NHE3 contribute to formation of DIS in the esophageal epithelium in patients with EoE.
METHODS

Human subjects
Healthy control subjects were defined as having no history of EoE diagnosis, 0 esophageal eosinophils per high-power field (hpf), and no evidence of esophagitis within distal esophageal biopsy specimens obtained during the same endoscopy procedure as the analyzed samples. EoE was defined as described in the recent consensus guidelines. 5 Specifically, patients needed to have 15 or more eosinophils in at least 1 hpf in an esophageal biopsy specimen, with other causes of esophageal eosinophilia excluded and without a response to acid suppression. The healthy control cohort consists of patients with a variety of nonspecific upper gastrointestinal complaints, including vomiting, loose stools, abdominal pain, and nausea who underwent endoscopy and biopsy and were demonstrated to have no histologic evidence of esophageal disease. RNAseq and validation quantitation RT-PCR (qRT-PCR) analyses and histology (eosinophils/hpf and DIS quantification) studies were performed on esophageal biopsy specimens. RNAseq and qRT-PCR analyses and histology (eosinophils/hpf and DIS) were performed on human esophageal biopsy specimens (healthy subjects, n 5 6; patients with EoE, n 5 10), as previously described (National Center Biotechnology Information Gene Expression Omnibus database under accession GSE58640; cohort 1). 24 The demographics of the healthy control subjects and patients with EoE are described in Fig E1 in this article's Online Repository at www.jacionline.org. The qRT-PCR and histopathologic (eosinophils/hpf) analyses were performed on a second independent cohort (healthy subjects, n 5 10; patients with EoE, n 5 10; cohort 2). The demographics of the patients and control subjects are described in Fig E1. RNAseq of human biopsy specimens. Esophageal biopsy RNA was isolated from control subjects and patients with EoE with active disease by using the RNeasy kit (Qiagen, Germantown, Md), according to the manufacturer's protocol. RNA libraries were prepared by using standard Illumina protocols (TrueSeq RNA LS Sample Prep V2; Illumina, San Diego, Calif) at the Cincinnati Children's Hospital Medical Center (CCHMC) Genetic Variation and Gene Discovery Core. RNAseq acquiring 100-bp reads from paired-end libraries was performed at the Genetic Variation and Gene Discovery Core Facility at CCHMC by using the Illumina HiSeq 2500. The paired-end sequencing reads were aligned against the GRCh37 genome model by using TopHat 2.04 with Bowtie 2.03. 34, 35 The separate alignments were then merged by using Cuffmerge 36 with UCSC gene models as a reference. Raw data were assessed for statistical significance by using a Welch t test with a Benjamini-Hochberg false discovery rate and threshold P value of less than .05 and a 2.0-fold cutoff filter in GeneSpring GX (Agilent Technologies, Santa Clara, Calif).
RNAseq of mature EPC2-ALI. RNA was isolated with the RNeasy kit (Qiagen), according to the manufacturer's instructions.
Assessment of RNA quality was performed by using the Agilent 2100 Expert Bioanalyzer (Agilent Technologies), and only those samples with an RNA integrity number of greater than 8 were chosen for sequencing. Next-generation sequencing analyses were performed by using the CCHMC Genetic Variation and Gene Discovery Core with the Illumina HiSeq 2500. Raw data were uploaded on Biowardrobe, 37 and reads per kilobase million values were calculated. Differentially expressed genes were assessed by using DEseq2.
GO analysis. Gene set enrichment analysis and candidate gene prioritization based on molecular function were determined by using ToppGene 38 with FDR Benjamini-Hochberg correction and a P value cutoff of .05. Heat maps were generated by using RStudio.
Pathologic analysis
Biopsy preparation. Formalin-fixed, paraffin-embedded esophageal biopsy sections were sectioned into 5-mm slides. After removal of paraffin and serial hydration, sections were stained with hematoxylin and eosin (H&E). H&E-stained slides were then imaged with an Olympus DP-72 microscope (Olympus, New York, NY).
Quantification of the intercellular space. The intercellular space was quantified as the percentage of intercellular area of the total area of the biopsy sample by using the Image-Pro Plus software (Media Cybernetics, Rockville, Md) automated space measurement function and calculated based on the ratio of intercellular area/total tissue area.
Quantitative PCR analysis
RNA samples were extracted from esophageal biopsy specimens, cultured primary cells, or EPC2-ALI cultures by using the RNeasy kit (Qiagen), according to the manufacturer's protocol. Purified RNA (300-500 ng) was DNAse treated and reverse transcribed to cDNA by using Superscript II RNase H Reverse Transcriptase (Thermo Fisher Scientific, Rockford, Ill), according to the manufacturer's instructions. cDNA for SLC9A3 and 18S was quantified by using real-time PCR with TaqMan Universal Supermix with the CFX96 Real-Time PCR Detection System. Quantitative PCR analysis was performed with the Bio-Rad CFX Manager Software (version 3.1; Bio-Rad Laboratories, Hercules, Calif). Primers for SLC9A3 and 18S were purchased for TaqMan assay (Thermo Fisher Scientific, Waltham, Mass).
Immunofluorescence staining
For immunofluorescence (IF) staining, formalin-or paraformaldehydefixed, paraffin-embedded esophageal biopsy specimens or EPC2-ALI cultures were sectioned, mounted on slides, and deparaffinized with standard histologic procedures. Slides were then permeabilized in Tris-EDTA (1 mmol/L, pH 9.0) with 0.1% Tween-20, and antigen exposure was performed at 1258C for 30 seconds in a decloaking chamber by using a pressure cooker. Slides were then blocked with 10% normal donkey serum for 1 hour, followed by overnight incubation of primary antibodies diluted in 10% normal donkey serum: NHE3 (Novus, Littleton, Colo) and CK13 (Invitrogen, Carlsbad, Calif). Slides were then washed and incubated with secondary antibody at room temperature for 1 hour. Slides were mounted with Fluoromount-G (SouthernBiotech, Birmingham, Ala) mounting solution. Fluorescence imaging was performed with the Zeiss Apotome fluorescent microscope (Zeiss, Oberkochen, Germany) with NIKON elements software (Nikon, Tokyo, Japan) and ImageJ software (National Institutes of Health, Bethesda, Md).
Primary cell preparation
Distal esophageal biopsy specimens were obtained from healthy control subjects or patients with EoE who underwent routine endoscopy, suspended in 1 mL of keratinocyte serum-free media (KSFM; Invitrogen) containing supplements (human epidermal growth factor [1 ng/mL], bovine pituitary extract [50 mg/mL], and 13 penicillin/streptomycin; Invitrogen), and then placed in a 60-mm dish in 3 mL of filter-sterilized (0.2 mm) Leibovitz L-15 media (Invitrogen) containing 115 U/mL collagenase, 1.2 U/mL Dispase, and 1.25 mg/mL BSA. The biopsy specimen was mechanically dispersed by using scissors to pieces of less than 1 mm in size and then incubated at 378C for 1 hour. The cell suspension was centrifuged at 500g for 5 minutes at 48C, and the pellet was washed twice with 5 mL of supplemented KSFM. Cells were suspended in 1 mL of 0.05% trypsin/EDTA for 10 minutes at 378C and agitated every 2 minutes. Trypsin activity was inhibited with soybean trypsin inhibitor (250 mg/L in 13 Dulbecco-PBS; 5 mL). Cells were pelleted by means of centrifugation, suspended in 1 mL of KSFM containing supplements, transferred to a 35-mm dish containing irradiated NIH 3T3 J2 fibroblasts (162,500 cells) and cultured at 378C in a 5% CO 2 atmosphere. Medium was changed at day 5 and every other day thereafter by using KSFM containing supplements. After epithelial cells became 60% to 70% confluent, they were dispersed from the plate by using 0.05% trypsin/EDTA for 10 minutes at 378C and agitated every 2 minutes. Trypsin digestion was inactivated by using soybean trypsin inhibitor, and cells were then passaged in KSFM containing supplements at 1 to 2 3 10 5 cells per 3 mL in a 60-mm dish. the Na 1 -dependent pH i change. pH i values are derived from the calibration curves described below. The statistical significance of the Na 1 -dependent pH i change was determined by using the Student t test (2-tailed). Cells were imaged with a Nikon Spectra X inverted fluorescent microscope with the excitation wavelength of 512 nm/440 nm and emission at 535 nm to record the BCECF AM fluorescence change. Cells were imaged by using a Zeiss LSM710 LIVE DUO confocal microscope with an excitation wavelength of 488 nm and emission wavelength of 640 nm/580 nm to record the SNARF-5F AM fluorescence change. S3226 (30 mmol/L) or 0.01% dimethyl sulfoxide (DMSO; vehicle) was applied throughout the experiment to inhibit NHE3 activity. The percentage S3226-sensitive Na 1 -dependent pH i recovery rate was calculated as the recovery rate as follows:
ðDMSO-treated 2 S3226-treatedÞ Ã 100=DMSO-treated percentage:
Quantification was performed on 10 to 20 cells randomly picked in each sample, and fluorescence intensity was measured with Nikon Elements microscope imaging software or ImageJ software (National Institutes of Health, Bethesda, Md). These fluorescence intensity values were then converted into pH values per calibration curve. A calibration curve was generated at the end of each experiment; BCECF AM or SNARF-5F AM intensity was calibrated against pH i when cells were exposed to the K 
EPC2-ALI culture
hTERT-EPC2 cells (hTERT-immortalized human esophageal keratinocytes) were a kind gift from Dr Anil Rustgi (University of Pennsylvania, Philadelphia, Pa), as previously described. 39 The air-liquid interface (ALI) culture system was previously described and characterized together with EPC2 cells.
28 EPC2 cells were grown to fully submerge on 0.4-mm pore size, permeable transwell inserts (Corning, Corning, NY) in KSFM (Life Technologies, Carlsbad, Calif). First, at day 0, cells were seeded on a permeable membrane and grown to single submerged layer after 3 days. Second, cells were then shifted to medium containing high [Ca 21 ] to induce tight junction formation ([Ca 21 ] 5 1.8 mmol/L). Third, on day 7, media were removed from the top chamber to induce differentiation and epithelial stratification at the ALI. Fourth, at day 12 (5 days after ALI), cells were treated with vehicle or cytokine (IL-13) in the presence and absence of SLC9A3 inhibitor S3226 (30 mmol/L), 40 as described in the figure legends.
Lentiviral transduction
EPC2 cells at 60% to 70% confluence were transduced with lentiviral particles containing Mission STAT6 short hairpin RNA (shRNA) TRC 0000019409 shRNA or Mission STAT3 (TRCN0000329887) shRNA (Sigma, St Louis, Mo) or Mission nontarget control shRNA (Sigma). All 3 shRNA lentiviruses were generated by the CCHMC Viral Core by using a 4-plasmid packaging system. Lentiviral particles were incubated with EPC2 cells for 6 hours at a multiplicity of infection of 0.5 to 10 for signal transducer and activator of transcription (STAT) 3 or control shRNA. For STAT6 shRNA, 10 to 50 mL of viral particles were added to the cells. All viral particles were added in the presence of 5 mg/mL Hexadimethrine bromide (Polybrene; Sigma).
During the first hour of incubation, cells were spun down at 1000g for 1 hour at room temperature. Six hours After transduction, cells were put in fresh KSFM, and 24 hours later, medium containing 1 mg/mL Puromycin (Thermo Fisher Scientific) was used for selection. Cells were grown under selective pressure and cultured as regular EPC2 cells. Stable knockdown of STAT6 and STAT3 in EPC2-ALI cultures was evaluated by using Western blotting. Results indicated an 80% reduction in STAT6 and 90% reduction in STAT3 expression, relatively, compared with that seen in empty control transduced cells.
Western blot
EPC2-ALI cultures were lysed by using protein lysis buffer (10% glycerol, 20 mmol/L Tris HCl [pH 7], 137 mmol/L NaCl, 2 mmol/L EDTA, and 1% NP-40 in H 2 O) supplemented with Halt protease inhibitor cocktail (Thermo Fisher Scientific). Proteins were then quantified with the bicinchoninic acid assay, and 20 mg of protein extracted together with protein-reducing buffer was loaded and separated on a 4% to 12% Bis-Tris gel and transferred to a nitrocellulose membrane (Life Technologies). Antibodies of NHE3 and a-actin were used for protein detection. The IRDye 800 CW goat anti-rabbit IgG (H1L; LI-COR, Lincoln, Neb) was used as the secondary antibody for detection. Western blot quantification was performed with Image Studio Lite (LI-COR).
pH-STAT assay
Acid secretion by confluent epithelium was quantitated by using pH-STAT (TIM856; Radiometer Analytical, Loveland, Colo) connected to an Ussing chamber system, as previously described.
41 EPC2-ALI cultures were mounted to an Ussing chamber containing unbuffered Ringer solution (145 mmol/L NaCl, 2 mmol/L KCl, 1 mmol/L MgCl 2 , 2 mmol/L CaCl 2 , and 5 mmol/L glucose) and gassed with 99.5% oxygen. Both the pH electrode and titrating burette are placed in the apical side chamber.
Extracellular pH was measured for 10 minutes or until a stable pH was achieved (<0.002 pH unit change/min) to measure the equilibrium extracellular pH without any titration. After the equilibrium period and extracellular pH measurements were obtained, the pH of the mucosal side was adjusted by titration to a set alkaline pH (pH 7.6) to create the electrochemical driving force for acid secretion. The titration rate (ie, the amount of alkaline injected by the machine to neutralize the acid secreted by EPC2-ALI culture to maintain the set pH) was used to measure the acid secretion rate.
Histologic analysis for EPC2-ALI cultures
EPC2-ALI cultures were treated as indicated in experiments and then fixed on transwell supports with 4% paraformaldehyde for 1 hour at room temperature. Fixed membranes underwent a series of dehydration steps, cleared in Histoclear solution, embedded in paraffin, and sectioned into 5-mm slides. The slides were stained by using H&E staining and imaged with an Olympus DP-72 microscope (Olympus).
Electron microscopy
EPC2-ALI cultures were treated as indicated in experiments, fixed with 3% glutaraldehyde, and submitted to the CCHMC Pathology Research Core for processing, sectioning, and transmission electron microscopy by using a Hitachi model H-7650 electron microscope at 80 kV with the AMT-600 image capture engine software.
Statistical analysis
The statistical significance of EPC2-ALI samples was established by using an unpaired t test (2-tailed) or 2-way ANOVA if there was more than 1 variable. For nonnormally distributed data from patients' biopsy specimens and primary cells derived from patients' biopsy specimens, the Mann-Whitney test was used, and correlation analyses were assessed with a Spearman correlation test. Graphing and statistical analyses were performed with GraphPad Prism (7.02; GraphPad Software).
RESULTS
Transmembrane transporter SLC9A3/NHE3 was specifically upregulated and correlated with eosinophil counts and DIS in patients with EoE
To begin to determine the potential involvement of transmembrane transporter activity in the histopathologic alterations of the esophageal epithelium in patients with EoE, we applied GO enrichment analysis of the 1607 differentially expressed RNA transcripts identified by means of RNAseq analyses of pediatric biopsy specimens from healthy control subjects and patients with EoE. 24 GO analysis revealed 50 individual GO nodes significantly dysregulated in the EoE transcriptome based on functional annotations and protein interaction networks (FDR-corrected P < .05, see Fig E2 in this article's Online Repository at www.jacionline.org). Of these GO nodes, 5 were related to transmembrane transporter activity (Fig 1, A) . A combinatory comparison of all 62 genes within these 5 GO nodes revealed that the most upregulated transmembrane transporter activity gene was SLC9A3, which encodes for NHE3 (Fig 1, B) . SLC9A3 was induced 33-fold in patients with EoE compared with healthy control subjects (Fig 1, C) . In contrast, expression of other members of the SLC9 family, including the ubiquitously expressed sodium-proton exchanger solute carrier family 9, subfamily A, member 1 (SLC9A1), also referred to as sodium-hydrogen exchanger family member 1, was not dramatically different between patients with EoE and healthy control subjects (Fig 1, D) . Correlation analyses revealed a positive correlation between the level of peak distal esophageal eosinophil count and SLC9A3 expression (r 5 0.7167, P < .05; Fig 1, E) . Notably, this was specific to SLC9A3 because we did not observe any correlation with SLC9A1 (r 5 0.3201, P > .05; Fig 1, E) , revealing a specific link between SLC9A3 expression and disease severity in patients with EoE.
To confirm these observations, we examined a second independent pediatric cohort (healthy control subjects, n 5 10; patients with active EoE, n 5 10), for which we had paired RNA and histologic biopsy samples from the same day of endoscopy. Consistent with our RNAseq analyses, quantitative PCR analyses revealed significant SLC9A3 overexpression in the pediatric EoE cohort (Fig 1, F) . Furthermore, we observed a positive Pearson correlation between SLC9A3 expression level and distal peak esophageal eosinophil numbers (r 5 0.9172, P < .0001; Fig 1, G) .
We next performed IF analyses to determine the cellular and spatial expression of NHE3 in esophageal biopsy specimens from healthy control subjects and patients with EoE. Consistent with our RNAseq and PCR analyses, we observed very little expression of NHE3 in healthy esophageal epithelium (Fig 1, H, upper panel) . The positive staining observed was restricted to the CK13 2 single-cell basal esophageal epithelial layer (Fig 1, H, upper  panel) . In patients with EoE, NHE3 protein expression was remarkably increased, localized to the esophageal basal cell layer, and expanded into the CK13 1 suprabasal layer (Fig 1, H, lower  panel) . Localization of NHE3 to the suprabasal zone, an area associated with DIS formation, led us to examine the relationship between SLC9A3 expression and DIS in esophageal biopsy specimens from patients with EoE. Notably, SLC9A3, but not SLC9A1, expression positively correlated with the percentage of DIS area in patients with EoE (r 5 0.8095, P <.05; Fig 1, I ). These cumulative data indicate specific upregulation of SLC9A3/NHE3 in the suprabasal layer of the esophageal epithelium in patients with EoE and that SLC9A3 expression correlates with esophageal eosinophilic inflammation and DIS.
Increased NHE3 function in IL-13-stimulated primary esophageal epithelial cells
The epithelial sodium-proton exchanger NHE3 is expressed predominantly in the apical membrane of the epithelium and is the principal mechanism for electroneutral exchange of (Apical / Baso) Na 1 and (Baso / Apical) H 1 and plays an important role in maintenance of pH i and regulation of cell volume. 42 Given IL-13's known role in upregulating the EoE transcriptome 18 and that the humanized anti-IL-13 mAb QAX576 has been shown to modulate expression of an anion transport activity node, 25 we examined the effect of IL-13 exposure on SLC9A3 expression in primary esophageal epithelial cells. We demonstrate upregulation of SLC9A3 expression in primary esophageal epithelial cells after IL-13 stimulation (Fig 2, A) .
To determine whether increased SLC9A3 expression was associated with altered NHE3 activity, we examined the effect of IL-13 exposure on pH i in primary esophageal epithelial cells. Notably, increased SLC9A3 expression coincided with a significant increase in baseline pH i (Fig 2, B) and Na 1 -dependent pH i recovery rate (Fig 2, C and D (Fig 1, C ) and heat map depicting expression level of SLC9A1-9 (Fig 1, D) . E, Correlation analysis of SLC9A3 or SLC9A1 expression and matched peak distal eosinophils/hpf in esophageal biopsy specimens (healthy control subjects [NL], 6; patients with EoE 5 10). F and G, Quantitative PCR analysis of SLC9A3 expression (Fig 1, F) and Spearman correlation relating SLC9A3 expression (Fig 1, G) and eosinophils/hpf in an independent validation cohort (healthy control subjects, 10; patients with EoE, 10). H, IF staining of esophageal biopsy sections from healthy control subjects (top panel) and patients with EoE (lower panel). . Fig 1, E , G, and I, Data are presented as relative expression over 18S. Fig 1, C, E-G, and I, Individual symbols represent individual patients. **P < .01 and ***P < .001.
epithelial cells (r 5 0.9503, P < .01; Fig 2, E) , suggesting that the increase in pH i recovery rate in IL-13-treated primary esophageal epithelial cells is predominantly caused by increased NHE3 expression. Addition of the NHE3-specific inhibitor S3226 (30 mmol/L) confirmed that the IL-13-induced increase in Na
1
-dependent pH i recovery rate was mediated predominantly by NHE3 (Fig 2, F) . IL-13 induces an EoE-like transcriptome, including increased transmembrane transporter activity and SLC9A3 overexpression, in an in vitro, matured, esophageal epithelial model system
To define the involvement of SLC9A3/NHE3 in regulation of pH i and DIS formation in a mature esophageal epithelial model system, we adapted an in vitro model developed from keratinocyte esophageal epithelial cells (EPC2) grown at the ALI. 28 EPC2s were grown under submerged conditions in low-calcium media (0.09 mmol/L, days 0-3), changed to high-calcium media (1.8 mmol/L, days 3-7), and then exposed to the ALI for 5 days in the presence of high calcium levels (1.8 mmol/L, days 7-12) to induce differentiation and formation of a mature stratified epithelium (Fig 3, A) . After maturation, EPC2-ALI cultures were stimulated with vehicle or IL-13, and RNAseq analyses were performed (days 12-14; Fig 3, A) . We show that IL-13 significantly dysregulated a total of 572 genes (P < .05, fold change > 2.0); notably, many of the most highly dysregulated genes included inflammatory genes associated with EoE, including CCL26 (7-fold), TNFAIP6 (9-fold), CDH26 (3-fold), and CAPN14 (5-fold), and also gene families located in the epidermal differentiation cluster on chromosome 1q21 (eg, IVL, LOR, S100A4, and S100A6; Fig 3, B , and see Table E1 in this article's Online Repository at www.jacionline. org). Consistent with these findings, comparative analyses of the IL-13-induced transcriptome changes in EPC2-ALI cultures with that of the EoE-specific transcriptome revealed significant overlap with the EoE-specific transcriptome (P < .0001; Fig 3, B) . GO analysis based on the biological process on IL-13-dysregulated genes revealed the most significant 15 individual GO biological process nodes associated with keratinization, epidermis development, skin development, keratinocyte differentiation, epidermal cell differentiation, and (Fig 2, D) and 50 individual cells from 5 different patients with active EoE (Fig 2, F) . Fig 2, A, B , D, and F, Data are represented as average 6 SEM. *P < .05, **P < .01, and ****P < .0001.
inflammatory response and GO pathways associated with formation of the cornified envelope, keratinization, and IL-4 and IL-13 signaling (FDR-corrected P < .05; see Table E2 in this article's Online Repository at www.jacionline.org).
To examine the effect of IL-13 on transmembrane transporter activity, we performed GO analysis based on the molecular function of the 572 genes and identified 6 nodes dysregulated significantly and related to transmembrane transport activity (FDR-corrected P <.05; Fig 3, C) . Of the 28 differentially expressed transmembrane transport activity genes in these 6 GO nodes, SLC9A3 was one of the most highly upregulated genes (Fig 3, D) .
IL-13 is known to signal through the Janus kinase/STAT pathway, in particular through a STAT3-and STAT6-dependent signaling pathway. 43 To determine the involvement of STAT3 and STAT6 in IL-13 induction of SLC9A3, we examined SLC9A3 mRNA expression in STAT3 and STAT6 shRNA-transduced EPC2-ALI cultures after IL-13 stimulation. Notably, STAT3 knockdown in EPC2-ALI cultures caused no significant reduction in IL-13-induced SLC9A3 expression compared with control shRNA-transduced EPC2-ALI cultures (Fig 3, E) . In contrast, STAT6 knockdown in EPC2-ALI cultures significantly ablated IL-13-induced SLC9A3 expression (50% reduction), suggesting that IL-13-induced STAT6 signaling is important for SLC9A3 expression in EPC2-ALI cultures (Fig 3, E) . These studies demonstrate that IL-13 induces SLC9A3 expression in EPC2-ALI cells in part through a STAT6-dependent mechanism. section) . B, Gene expression change of IL-13-stimulated EPC2-ALI versus nontreated EPC2-ALI cultures compared with that of patients with active EoE versus healthy control subjects. Fold changes were calculated from RNAseq of EPC2-ALI cultures and patient samples. Spearman correlation analysis was applied to analyze these 23,660 genes. C, GO analysis of 572 genes that were significantly dysregulated by IL-13 treatment of EPC2-ALI cultures (fold change > 2, P < .05) identified 6 GO nodes related to transmembrane transporter activity. D, Heat map depicting expression level of 46 individual genes within the transmembrane transporter activity GO nodes that are significantly dysregulated in EPC2-ALI cultures after IL-13 stimulation. E, Reads per kilobase million values indicating SLC9A3 expression level in empty control (CTRL), STAT3 lentiviral knockdown (STAT3KD), and STAT6 lentiviral knockdown (STAT6KD) EPC2-ALI cultures treated with vehicle (Veh) or IL-13 (n 5 3 per treatment). **Adjusted P < .01 and ***adjusted P < .001.
IL-13-induced NHE3 expression and function in differentiated esophageal epithelial cells
Using this mature EPC2-ALI model system, we show that IL-13 stimulation of EPC2-ALI multicell layer induced an increase in SLC9A3 mRNA (Fig 4, A) and NHE3 protein (Fig 4, B and C) expression. IF analyses revealed that NHE3 was barely expressed in vehicle-treated EPC2-ALI multicell layer (Fig 4, D, top panel) . In contrast, we observed a significant increase in NHE3 expression A-C, Quantitative PCR (Fig 4, A) , Western blot analysis (Fig 4, B) , and Western blot quantification (Fig 4, C) of SLC9A3/NHE3 expression in EPC2-ALI cultures after a 72-hour treatment with vehicle (Veh) or IL-13 (100 ng/mL). Ct, Cycle threshold; MW, molecular weight. D, IF staining of vehicle-stimulated (top panel) or IL-13-stimulated (lower panel) EPC2-ALI cultures. NHE3 (red) and nuclei (blue) are shown. Images are presentative of 3 samples per group. Magnification 3400. E, Schematic view of pH-STAT assay. See the Methods section for a detailed protocol. F, Baseline extracellular pH (pH e ) of EPC2-ALI multicell layer cultures treated with vehicle or IL-13 for 72 hours. DMSO (0.1%) or S3226 (30 mmol/L) was added to both sides of the chamber during the experiment (n 5 6-11 samples per group from 5 individual experiments). G and H, Amount of Ba(OH) 2 injection over time (Fig 4, G) and Ba(OH) 2 injection rate (Fig 4, H) measured for EPC2-ALI multicell layer cultures treated with vehicle or IL-13 for 72 hours. DMSO (0.1%) or S3226 (30 mmol/L) is added to both sides of the chamber during experiment (n 5 6-11 samples per group from 5 individual experiments). Fig 4, A, C, F, and H, Data are represented as average 6 SEM. *P < .05. n.s., Not significant.
in EPC2-ALI multicell layer following IL-13 exposure; comparable with what we observed in biopsy samples from patients with EoE. IF analyses revealed that NHE3 was localized predominantly to the basal and suprabasal layer of the epithelium in IL-13-treated EPC2-ALI cultures (Fig 4, D, lower panel) .
To examine NHE3 function in mature EPC2-ALI cultures, we measured proton secretion rates in an Ussing chamber system fitted with pH-STAT (Fig 4, E) . We show that IL-13 stimulation reduced extracellular pH compared with vehicle-treated control values (extracellular pH [pH e ]: 6.82 vs 6.97, respectively; P < .05), indicating altered acid-base transport. Notably, the reduction in extracellular pH was abrogated with exposure to the specific NHE3 inhibitor S3226 (Fig 4, F) , indicating NHE3-dependent proton extrusion. To measure the rate of acid extrusion by the mature EPC2-ALI, the buffer on the apical side was adjusted to an alkaline pH (pH 7.6; Ba[OH] 2 ) to generate the electrochemical gradient necessary to stimulate acid secretion, and the amount of alkali Ba(OH) 2 required to maintain this condition (pH 7.6) was continuously monitored with pH-STAT (Fig 4, G) . We show that IL-13 stimulation of mature EPC2-ALI multicell layer led to increased Ba(OH) 2 injection to counterbalance H 1 secretion from the tissue and maintain a pH of 7.6 (Fig 4, G) .
S3226 was added to the apical buffer to determine the involvement of NHE3 in apical acid secretion function in the mature EPC2-ALI cultures. Notably, the acid-secretion rate in IL-13-stimulated mature EPC2-ALI multicell layer was significantly abrogated with S3226, indicating NHE3-dependent secretion (Fig 4, H) . These observations indicate an IL-13-induced increase in NHE3-dependent acid secretion in EPC2-ALI cultures.
Increased SLC9A3 expression and activity is linked to DIS formation Given the observed association between NHE3 and acid secretion in EPC2-ALI cultures and the correlation between SLC9A3 expression and DIS formation in esophageal biopsy samples from patients with EoE (Figs 1, I, and 4, H, respectively) , we examined the relationship between NHE3 function and DIS formation in a mature EPC2-ALI multicell layer. IL-13 stimulation of a EPC2-ALI multicell layer induced DIS formation within the basal and suprabasal layer of EPC2-ALI cells, as evidenced by spaces between cells (Fig 5, A) . Electron microscopy analyses revealed alteration in the intercellular junctional structures of esophageal cells, with the appearance of expanded or dilated intercellular areas (Fig 5, B; black arrows) . Notably, the DIS are sealed by lateral membranes that are of close apposition and tethered by intercellular junctional proteins, such as desmosomes (Fig 5, B) .
To determine the requirement of NHE3 activity in DIS formation, we stimulated EPC-ALI multicell layer with IL-13 in the presence of the NHE3 inhibitor S3226 (Fig 5, C and D) . Notably, we show that the IL-13-induced DIS within the suprabasal layer in EPC2-ALI cells were diminished in the presence of S3226 (Fig 5, C and D) . Collectively, we concluded that NHE3 has an important role in IL-13-induced DIS formation in esophageal cells.
DISCUSSION
EoE is characterized by histopathologic manifestations, including BZH and DIS. The underlying molecular processes that drive these pathologic manifestations remain largely unexplored. Here we demonstrate (1) dysregulation of transmembrane transporter activity gene networks in esophageal biopsy specimens from patients with EoE; (2) increased expression of the Na 1 -H 1 exchanger SLC9A3/NHE3 in esophageal biopsy specimens from patients with EoE and positive correlation of this increased expression with DIS area and eosinophil infiltration; (3) increased SLC9A3 expression and NHE3 activity in primary esophageal epithelial cells and in response to IL-13 stimulation in a mature EPC2-ALI model system; and (4) reduction of IL-13-induced DIS formation in EPC2-ALI cells by pharmacologic antagonism of NHE3 activity. Collectively, we have identified a role for SLC9A3/NHE3 in IL-13-induced DIS formation in the esophageal epithelium and provide evidence for involvement of this pathway in the histopathologic manifestations of EoE.
The cytokine IL-13 has an important role in driving the underlying allergic inflammatory cascade and histopathologic (Fig 5, A) and electron microscopy (Fig 5, B) of EPC2-ALI multicell layer cultures stimulated with vehicle or IL-13 (100 ng/mL) for 72 hours and showing DIS (black arrows) in only IL-13-treated cells. C, H&E staining of EPC2-ALI multicell layer cultures stimulated with vehicle or IL-13 (100 ng/mL) in the presence and absence of S3226 (30 mmol/L) for 72 hours. D, DIS formation (percentage of total area) was quantitated by using morphometric analyses and expressed as the mean 6 SEM (n 5 3 independent experiments). ****P < .0001. features of EoE. [22] [23] [24] This notion is supported by observations that stimulating esophageal cells with IL-13 leads to a transcript signature that partially overlaps the esophageal EoE transcriptome. 18 Furthermore, although the primary outcome of a greater than 75% decrease in peak eosinophil counts at week 12 was not met, treating patients with EoE with anti-IL-13 (QAX576) reduced intraepithelial esophageal eosinophil counts and led to improvement in the EoE transcriptome and clinical symptom, such as dysphagia, in adults with EoE. 25 Our observation of increased SLC9A3 expression in tissue samples from patients with EoE and in both primary esophageal epithelial and EPC2-ALI cultures following IL-13 stimulation was surprising given that SLC9A3/NHE3 expression and function are predominantly associated with induction of T H 1 proinflammatory cytokines, including IFN-g and TNF.
44 IFN-g and TNF are thought to modulate SLC9A3 expression through protein kinase A-mediated phosphorylation of Sp1 and Sp3 transcription factors. 44 TNF has also been shown to alter NHE3 activity by stimulating protein kinase Ca-dependent internalization of NHE3. 45 Stimulation of EPC2-ALI cultures with other pro-type 2 cytokines, such as IL-25 and IL-33, did not lead to induction of SLC9A3/NHE3 mRNA expression (results not shown). Notably, a recent study in kidney and intestinal epithelial cells (Caco-2) reported a STAT3-dependent increase in SLC9A3 expression through the recruitment of transcriptional factor Sp1 and Sp3. 46 IL-13 is known to signal through the Janus kinase/STAT pathway, in particular through a STAT3-and STAT6-dependent signaling pathway. 43 We reveal that STAT6 signaling plays a significant role in IL-13-induced SLC9A3 expression in EPC2-ALI cultures. Examining the SLC9A3 promoter did not reveal the presence of STAT6 binding IFN-g activation site (GAS) elements (results not shown), suggesting that STAT6 might indirectly modulate SLC9A3 expression. Notably, there are recent reports of IL-13-induced, STAT6-dependent activation of early growth response gene 1 (EGR1) signaling pathways in patients with EoE, 47, 48 and previous studies in intestinal epithelial cells have revealed that overexpression of EGR1 promotes SLC9A3/NHE3 expression and activity. 49 We are currently further pursuing the molecular basis of IL-13 transcriptional regulation of SLC9A3 expression. SLC9A3, as a member of the Na 1 /H 1 exchanger family, drives Na 1 -dependent extrusion of H 1 and is primarily involved in the regulation of pH i and acid-protective mechanisms. [50] [51] [52] [53] A consequence of Na 1 -dependent acid extrusion in a multilayered stratified epithelium, such as the esophageal epithelium, is acidification of the intercellular spaces. 54 In well-perfused tissues, where there are short diffusion distances and good cell-to-capillary diffusive coupling, the acid is rapidly buffered by phosphates, proteins, and HCO 3 2 . 55 However, in stratified epithelium that is undergoing rapid and sustained cellular proliferation, the diffusion distances are increased, leading to often-inadequate capillary perfusion, which limits the capacity of the intercellular acid-protective mechanisms and neutralization of the acidified intercellular spaces. The accumulation of acid [H 1 ] in the intercellular spaces permits formation of an electrochemical gradient and ion diffusion, creating an osmotic force for water flux and dilation of the intercellular spaces. 56, 57 In patients with EoE, there is significant esophageal epithelial basal zone expansion, and the basal cell layer can exceed 15% of the total epithelial thickness. 58 We speculate that the esophageal proliferative response and the thickening of the suprabasal layer of the esophageal epithelium in patients with EoE increases the diffusion distances, thus causing the intercellular acid-protective mechanisms to become inefficacious leading to DIS.
Consistent with the concept of esophageal epithelial intercellular acid as a primary driver for DIS in EoE, luminal acid has been shown to drive acidification of the intercellular spaces and DIS in patients with nonerosive reflux disease. [55] [56] [57] 59 Furthermore, in support of this concept, a recent study reports a strong positive correlation between BZH and DIS (r 2 > _ 0.67) in both proximal and distal biopsy samples from pediatric patients with EoE. 60 Interestingly, the increased esophageal intercellular acid in nonerosive reflux disease is thought to activate afferent neurons (nociceptors) within the esophageal epithelium, leading to development of heartburn. 59, 61 Intriguingly, although not common, EoE is also associated with the development of heartburn. 4 SLC9A3's role in the regulation of pH i might not simply be in response to dysregulation of pH i but also in part fulfilling a larger role in regulation of esophageal epithelial proliferation. Moreover, intracellular pH plays an important role in many cellular functions, including proliferation 62 and apoptosis. 63 In tumor cells pH i is often increased compared with that in normal cells, and it is thought that the alkaline pH i provides an optimal environment for DNA synthesis relative to enzyme function. 64 Consistent with this, growth factors, such as epidermal growth factor and platelet-derived growth factor, stimulate a rapid increase in pH i , which is a critical requirement for entry of mitogen-stimulated quiescent cells into the S phase of the cell cycle. 65, 66 Experimental studies have identified an important role for NHE family members in the growth factor-induced increase in pH i and cellular proliferation. 67, 68 For example, pharmacologic abrogation of Na 1 -dependent extrusion of H 1 and increase in pH i in growth factor-stimulated mouse bone marrow-derived macrophage inhibited DNA synthesis and prevented the progression into the S phase. 67 Furthermore, the rapid and transient mitogen-induced increase in sodium-hydrogen exchanger member 1 (NHE1) activity and pH i during G 2 /M entry and transition is ablated in NHE1 mutant fibroblasts. 68 Notably, increasing the pH i in the absence of NHE1 activity was sufficient to restore CDC2 activity and promote G 2 /M entry and transition and cellular proliferation, indicating that the NHE1-driven increase in pH i is an important checkpoint for progression to G 2 phase of the cell cycle and mitosis. 68 We speculate that IL-13 induction of SLC9A3/NHE3 might be a critical requirement for esophageal epithelial cell proliferation through regulating pH i .
Notably, we have demonstrated previously that overexpression of IL-13 in mice leads to esophageal cell proliferation. 69 Here we show colocalization of NHE3 expression within the esophageal basal proliferative zone in esophageal biopsy samples from patients with EoE and IL-13-treated EPC2-ALI cultures. Furthermore, we show that stimulating EPC2-ALI cells with IL-13 induces SLC9A3, but not SLC9A1 expression and that treating mature EPC2-ALI cells with the pan-NHE inhibitor ethylisopropylamiloride attenuated IL-13-induced proliferation (see Fig E3 in this article' s Online Repository at www.jacionline.org). These findings support the necessity of an NHE in IL-13-induced proliferation in an esophageal epithelial model system in vitro, and given the overexpression, localization, and function of NHE3, we conjecture that pH i balance is a critical component of the proliferative response induced by IL- 13 70, 71 Our GO analysis supports dysregulation of these mechanisms in patients with EoE, identifying that 5 of the 50 individual GO nodes generated from genes significantly dysregulated in patients with EoE are correlated tightly with the transmembrane ion transport activity. Notably, several of the most dysregulated genes were part of the pH i regulatory circuit, including Cl 2 /HCO 3 2 exchangers (SLC26A4, SLC4A2, and SLC4A8) and carbonic anhydrases. These functional analyses support the concept of pH i pathways being active in primary esophageal epithelial cells in patients with EoE.
The demonstration that a significant decrease in DIS with steroid therapy or elimination diet in patients with EoE is associated with symptom improvement 31 indicates an association between DIS and the cause of EoE. We demonstrate a role for SLC9A3/NHE3 and Na
1
/H
1 exchange in DIS formation, one of the histopathologic manifestations of EoE. Given our observations, one would predict that using NHE3 antagonists (systemically or topically) might be a therapeutic approach for reducing DIS and thus normalizing associated esophageal caliber in patients with EoE. Notably, the NHE3-specific inhibitor tenapanor is in phase 3 clinical trials for the treatment of cardiorenal and gastrointestinal disease. 72 Tenapanor has been shown to reduce sodium uptake, resulting in reduction in pH i . 72 Given the contribution of DIS to esophageal barrier dysfunction and facilitating food allergen exposure, considering potential use of NHE3 inhibitors for EoE is warranted.
In summary, we identified a relationship between SLC9A3/NHE3 expression and activity with DIS in patients with EoE. Mechanistically, we show that IL-13 stimulates SLC9A3 expression and NHE3 activity (through pH i ) and that these were associated with esophageal epithelial DIS. Inhibiting NHE activity attenuated esophageal epithelial DIS formation, providing rationale for the therapeutic use of NHE3 antagonists for reducing DIS and DIS-associated esophageal pathophysiologic manifestations in patients with EoE.
Key messages
d The EoE transcriptome consists of altered expression of gene networks associated with regulation of pH i and acid-protective mechanisms.
d There is increased expression of SLC9A3 within the basal layer of esophageal biopsy specimens from patients with EoE, and this expression correlated positively with disease severity (eosinophils/hpf) and DIS.
d IL-13-induced SLC9A3 expression and Na 1 -dependent proton secretion and SLC9A3 activity correlated positively with DIS formation.
d IL-13-mediated Na 1 -dependent proton secretion was the primary intracellular acid-protective mechanism within the esophageal epithelium.
d SLC9A3-dependent transport is required for IL-13-induced DIS formation.
